The double-blind, placebo-controlled, crossover clinical study examined 12 healthy volunteers who were randomized to receive two capsules of 250mg of CAPROS (a patented, GRAS affirmed, highly standardized Phyllanthus emblica extract containing Emblicanin-A, Emblicanin-B, Punigluconin and Pedunculagin as bioactives) BID or two matching placebo capsules BID for 14
days. Pharmacodynamic parameters such as heart rate, augmentation pressure, augmentation index (AIx), subendocardial viability ratio (SEVR), radial and aortic blood pressure (BP) were recorded before and after the cold pressor test at baseline and at the end of treatment. After a washout period of 14 days, subjects crossed over to the other treatment and the same test procedure was repeated. Safety assessments were done at baseline and at the end of treatment.
The study was conducted by researchers at the Department of Clinical Pharmacology and Therapeutics at the Nizam’s Institute of Medical Sciences in Hyderabad, India and published in peer-reviewed journal, Pharmacognosy Research.
“We are very excited with the results of this study which suggests that CAPROS may help people cope with cold stress induced cardiovascular changes", says Natreon CEO, Dr. Sanni Raju. "This study further substantiates the cardiovascular health benefits of CAPROS and is an excellent addition to the collection of studies which have been conducted to date. We look forward to the publication of several additional studies in the following months" he added.
For more information: www.natreoninc.com